Pulse Biosciences (NASDAQ:PLSE) Trading Up 15.7% – Should You Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares rose 15.7% on Friday . The stock traded as high as $43.43 and last traded at $44.2560. Approximately 166,933 shares traded hands during trading, a decline of 51% from the average session volume of 337,567 shares. The stock had previously closed at $38.24.

Analysts Set New Price Targets

Several research firms have recently weighed in on PLSE. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Canaccord Genuity Group assumed coverage on Pulse Biosciences in a report on Thursday, June 4th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pulse Biosciences currently has an average rating of “Moderate Buy” and an average price target of $32.33.

Pulse Biosciences Price Performance

The firm has a market capitalization of $2.93 billion, a PE ratio of -38.36 and a beta of 1.61. The firm has a 50-day simple moving average of $28.66 and a 200-day simple moving average of $23.51.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The firm had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Equities analysts expect that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Insider Buying and Selling

In other Pulse Biosciences news, CEO Paul A. Laviolette purchased 15,000 shares of the business’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $19.69 per share, for a total transaction of $295,350.00. Following the purchase, the chief executive officer owned 15,000 shares of the company’s stock, valued at approximately $295,350. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert W. Duggan acquired 660,233 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $19.69 per share, with a total value of $12,999,987.77. Following the completion of the acquisition, the director owned 48,211,433 shares in the company, valued at approximately $949,283,115.77. This represents a 1.39% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 74.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new position in Pulse Biosciences during the second quarter worth $1,196,000. GSA Capital Partners LLP bought a new position in shares of Pulse Biosciences during the second quarter valued at approximately $290,000. Bank of America Corp DE raised its holdings in Pulse Biosciences by 8.2% in the first quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock worth $18,698,000 after purchasing an additional 65,884 shares in the last quarter. Cetera Investment Advisers purchased a new stake in Pulse Biosciences in the first quarter valued at about $387,000. Finally, Tudor Investment Corp ET AL purchased a new stake in Pulse Biosciences during the 4th quarter valued at about $382,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.